100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based ...

Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside the checkpoint inhibitor ...

Immune checkpoint inhibitors are a form of cancer immunotherapy successfully used to treat a wide range of cancers. However, ...

Recent Publication and Growing Industry Focus on Immune-Priming Strategies Support Continued Evaluation of Gedeptin(R) as a ...

New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications from cancer drugs, known as immune checkpoint ...

New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications from cancer drugs, known as immune checkpoint ...

Lung immune prognostic index (LIPI) is associated with survival outcomes in patients with non-small cell lung cancer (NSCLC) receiving immunotherapy, but the association with the occurrence of ...

ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...

The cut-off value of estrogen receptor (ER) and progesterone receptor (PgR) to define the positivity of ER and PgR had been 10% by immunohistochemistry (IHC) staining until 2010 when the American ...

Immune checkpoint inhibitors are well known as a form of cancer treatment. Researchers at UZH have now identified a new, important function of these inhibitors: promotion of tissue healing. This ...

A recent study found that monthly prices of checkpoint inhibitors decreased only slightly from 2015 to 2024, with declines in annual average sales prices ranging from 0.21% to 4.85%. "Prices of ...

An immune checkpoint inhibitor already approved for advanced cancers is set to become a new standard of care in the adjuvant setting for high-risk cutaneous squamous cell carcinoma (CSCC) across ...